Top

Drugs

Published in:

01-05-2011 | Review Article

End-Organ Protection in Patients with Hypertension

Focus on the Role of Angiotensin Receptor Blockers on Renal function

Authors: Giuliano Tocci, Professor Massimo Volpe, MD, FAHA, FESC

Published in: Drugs | Issue 8/2011

Abstract

The renin-angiotensin system (RAS) plays a key role in a number of pathophysiological mechanisms that are involved in the development and progression of cardiovascular and renal disease. For these reasons, pharmacological antagonism of this system, particularly the blockade of formation or the receptor antagonism of angiotensin II, has been demonstrated to be an effective and safe strategy to reduce the burden of cardiovascular disease. Among different drug classes, angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) have provided an excellent alternative to ACE inhibitors, representing a more selective and a better tolerated pharmacological approach to interfere with the RAS. Results derived from large, international, randomized clinical trials have consistently indicated that ARB-based therapeutic strategies may effectively provide cardiovascular and renal disease prevention and protection in different clinical conditions across the entire cardiovascular continuum.

This article reviews the pathophysiological rationale of RAS involvement in the pathogenesis of renal diseases, focusing on the beneficial effects provided by ARBs in terms of renal protection.

Volpe M, Tocci G, Pagannone E. Angiotensin II-receptor antagonist in the treatment of hypertension. Curr Hypertens Rep 2005 Aug; 7(4): 287–93PubMedCrossRef

Ruilope LM, Volpe M. Treating hypertension with angiotensin II receptor blockers: a step ahead of blood pressure reduction? High Blood Press Cardiovasc Prev 2005; 12(1): 9–15CrossRef

Tocci G, Sciarretta S, Facciolo C, et al. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Rev Cardiovasc Ther 2007 Jul; 5(4): 767–76PubMedCrossRef

Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008; 68(9): 1207–25PubMedCrossRef

Podar T, Tuomilehto J. The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications. Drugs 2002; 62(14): 2007–12PubMedCrossRef

Volpe M, Tocci G, Pagannone E. Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensin-aldosterone system. J Am Soc Nephrol 2006 Apr; 17 (4 Suppl. 2): S36–43PubMedCrossRef

Volpe M, Tocci G. Therapeutic implications of recent megatrials in hypertension: in favor of new drugs. J Nephrol 2007 Nov–Dec; 20 Suppl. 12: S12–8PubMed

Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 Jan; 28(1): 88–136

Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007 Sep; 25(9): 1751–62PubMedCrossRef

10.

Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007 Sep; 14 Suppl. 2: S1–113PubMedCrossRef

11.

Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan 15–21; 365(9455): 217–23PubMed

12.

Staessen JA, Wang J, Bianchi G, et al. Essential hypertension. Lancet 2003 May 10; 361(9369): 1629–41PubMedCrossRef

13.

Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360(9349): 1903–13PubMedCrossRef

14.

Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 Jun 27; 165(12): 1410–9PubMedCrossRef

15.

Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008 May 17; 336(7653): 1121–3PubMedCrossRef

16.

Schmieder RE, Schlaich MP, Klingbeil AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998 Mar; 13(3): 564–9PubMedCrossRef

17.

Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004 Oct 9; 329(7470): 828–39PubMedCrossRef

18.

Boersma E, Keil U, De Bacquer D, et al. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003 Oct; 21(10): 1831–40PubMedCrossRef

19.

Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 2010 May 26; 303(20): 2043–50PubMedCrossRef

20.

Alderman MH, Ogihara T. Global challenge for overcoming high blood pressure: Fukuoka Statement, 19 October 2006 [letter]. J Hypertens 2007 Mar; 25(3): 727PubMedCrossRef

21.

Alderman MH, Furberg CD, Kostis JB, et al. Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens 2002 Oct; 15 (10 Pt 1): 917–23PubMedCrossRef

22.

Volpe M, Alderman MH, Furberg CD, et al. Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens 2004 Nov; 17 (11 Pt 1): 1068–74PubMed

23.

Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998 Jan 6–13; 97(1): 48–54PubMedCrossRef

24.

Volpe M. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. Int J Clin Pract 2008 Jan; 62(1): 97–108PubMedCrossRef

25.

Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004 Nov 4; 351(19): 1941–51PubMedCrossRef

26.

Redon J. Treatment of patients with essential hypertension and microalbuminuria. Drugs 1997 Dec; 54(6): 857–66PubMedCrossRef

27.

Volpe M, Musumeci B, De Paolis P, et al. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens 2003 Aug; 21(8): 1429–43PubMedCrossRef

28.

De Paolis P, Porcellini A, Savoia C, et al. Functional crosstalk between angiotensin II and epidermal growth factor receptors in NIH3T3 fibroblasts. J Hypertens 2002 Apr; 20(4): 693–9PubMedCrossRef

29.

Johnston CI. Biochemistry and pharmacology of the reninangiotensin system. Drugs 1990; 39 Suppl. 1: 21–31PubMedCrossRef

30.

Ribeiro AB, Kohlmann Jr O, Saragoca MA, et al. The reninangiotensin system in the control of systemic arterial pressure. Drugs 1985; 30 Suppl. 1: 6–12PubMedCrossRef

31.

Ferrario CM. Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension: an overview. Drugs 1990; 39 Suppl. 2: 1–8PubMedCrossRef

32.

van Hooft IM, Grobbee DE, Derkx FH, et al. Renal hemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with hypertensive and normotensive parents. N Engl J Med 1991 May 9; 324(19): 1305–11PubMedCrossRef

33.

Norris K, Vaughn C. The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. Expert Rev Cardiovasc Ther 2003 May; 1(1): 51–63PubMedCrossRef

34.

The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992 Sep 3; 327(10): 685–91CrossRef

35.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991 Aug 1; 325(5): 293–302CrossRef

36.

The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987 Jun 4; 316(23): 1429–35CrossRef

37.

Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992 Sep 3; 327(10): 678–84PubMedCrossRef

38.

Biollaz J, Durr J, Brunner HR, et al. Escape from mineralocorticoid excess: the role of angiotensin II. J Clin Endocrinol Metab 1982 Jun; 54(6): 1187–93PubMedCrossRef

39.

Boehm M, Nabel EG. Angiotensin-converting enzyme 2: a new cardiac regulator. N Engl J Med 2002 Nov 28; 347(22): 1795–7PubMedCrossRef

40.

Laight DW. Therapeutic inhibition of the renin angiotensin aldosterone system. Expert Opin Ther Pat 2009 Jun; 19(6): 753–9PubMedCrossRef

41.

Strippoli GF, Bonifati C, Craig M, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006; (4): CD006257

42.

Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 Sep 20; 345(12): 870–8PubMedCrossRef

43.

Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002 Aug 6; 106(6): 672–8PubMedCrossRef

44.

Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep 20; 345(12): 861–9PubMedCrossRef

45.

Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep 20; 345(12): 851–60PubMedCrossRef

46.

Bohm M, Thoenes M, Danchin N, et al. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens 2007 Nov; 25(11): 2317–24PubMedCrossRef

47.

Sciarretta S, Pontremoli R, Rosei EA, et al. Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens 2009 Feb; 27(2): 410–7PubMedCrossRef

48.

Haller H, Ito S, Izzo Jr JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011 Mar 10; 364(10): 907–17PubMedCrossRef

49.

Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359(9311): 995–1003PubMedCrossRef

50.

Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007 Sep; 25(9): 1921–6PubMedCrossRef

51.

Ohishi M, Takagi T, Ito N, et al. Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study. Hypertens Res 2007 Dec; 30(12): 1187–92PubMedCrossRef

52.

Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007 Jun; 30(6): 1577–8PubMedCrossRef

53.

Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004 Nov 4; 351(19): 1952–61PubMedCrossRef

54.

Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000 Dec 9; 321(7274): 1440–4PubMedCrossRef

55.

Menne J, Farsang C, Deak L, et al. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens 2008 Sep; 26(9): 1860–7PubMedCrossRef

56.

Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10; 358(15): 1547–59PubMedCrossRef

57.

Imai E, Ito S, Haneda M, et al. Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design. Hypertens Res 2006 Sep; 29(9): 703–9PubMedCrossRef

58.

Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359(9311): 1004–10PubMedCrossRef

59.

Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For End-point Reduction (LIFE) substudy. JAMA 2002 Sep 25; 288(12): 1491–8PubMedCrossRef

60.

Os I, Franco V, Kjeldsen SE, et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention For Endpoint Reduction in Hypertension Study. Hypertension 2008 Apr; 51(4): 1103–8PubMedCrossRef

61.

Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005 Mar 1; 45(5): 705–11PubMedCrossRef

62.

Ibsen H, Wachtell K, Olsen MH, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004 Sep; 22(9): 1805–11PubMedCrossRef

63.

Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005 Feb; 45(2): 198–202PubMedCrossRef

64.

Estacio RO, Coll JR, Tran ZV, et al. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 2006 Dec; 19(12): 1241–8PubMedCrossRef

65.

Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008 Aug 16; 372(9638): 547–53PubMedCrossRef

Title: End-Organ Protection in Patients with Hypertension
Focus on the Role of Angiotensin Receptor Blockers on Renal function
Authors: Giuliano Tocci
Professor Massimo Volpe, MD, FAHA, FESC
Publication date: 01-05-2011
Publisher: Springer International Publishing
Published in: Drugs / Issue 8/2011
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/11591350-000000000-00000

At a glance: The STEP trials

Springer Medicine

End-Organ Protection in Patients with Hypertension

Focus on the Role of Angiotensin Receptor Blockers on Renal function

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2011

Efficacy and Safety of Long-Acting Reversible Contraception

Ipilimumab

Denosumab

Molecular Targeted Therapy in Ovarian Cancer

New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis

Botulinum Toxin A (Dysport®)